Dehydroeffusol

Research use only, not for human use.

Dehydroeffusol possesses anti-cancer, anxiolytic and sedative properties. Dehydroeffusol inhibits gastric cancer cell growth and tumorigenicity by selectively inducing tumor-suppressive endoplasmic reticulum stress and a moderate apoptosis.

Dehydroeffusol possesses anti-cancer, anxiolytic and sedative properties. Dehydroeffusol inhibits gastric cancer cell growth and tumorigenicity by selectively inducing tumor-suppressive endoplasmic reticulum stress and a moderate apoptosis.(In Vitro):Dehydroeffusol selectively activated the intracellular tumor suppressive stress response by promoting the overexpression of the key ER stress marker DNA damage-inducible transcript 3 (DDIT3), through upregulation of activating transcription factor 4 (ATF4). Concurrently, Dehydroeffusol suppressed the expression of the cell survival and ER stress marker glucose regulated protein of molecular mass 78 (GRP78) via downregulation of the transcription factor ATF6. In addition, Dehydroeffusolmarkedly activated the stress response signaling pathway MEKK4-MKK3/6-p38-DDIT3, but significantly inhibited ERK signaling.

Dehydroeffusol suppresses the expression of vasculogenic mimicry key gene VE-cadherin.Dehydroeffusol decreases the MMP2 expression and activity in gastric cancer cells.

——

5-Ethenyl-1-Methylphenanthrene-2,7-Diol | Dehydro Effusol

Metabolic Enzyme/Protease

MMP

MMP

——

——

137319-34-7

250.297

C17H14O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (399.54 mM)

Cc1c(O)ccc2c1ccc1cc(O)cc(C=C)c21

——

(-20℃)

With Ice Pack

≥ 2 years